All results
17 results for biomarkers als
-
TRACK-FA
This is a natural history study prospectively investigating neuroimaging markers of disease progression in children and adults with Friedreich ataxia (FA).…
- Ages
- 5 Years - N/A
- Sexes
- All
-
Comprehensive Outcomes for After Cancer Health (COACH)
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have…
- Ages
- 18 Years - N/A
- Sexes
- All
-
VITALISScE
This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype called…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT…
- Ages
- 18 Years - N/A
- Sexes
- All
-
TAPUR: Testing FDA Approved Drugs That Target Specific Abnormal Tumor Genes in Pts w/Advanced Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a…
- Ages
- 12 Years - N/A
- Sexes
- All
-
Bio-BOOST
BioBOOST is a multicenter, observational study of the effect of derangements in brain physiologic parameters on brain injury biomarker levels in patients with…
- Ages
- 18 Years - N/A
- Sexes
- All
-
NIH AIM 2 - Low Dose Pioglitazone in NASH
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…
- Ages
- 21 Years - 75 Years
- Sexes
- All
-
Immunotherapy for Patients With Advanced Kidney Cancer, The PDIGREE Study
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Testing the Combination of ZEN-3694 and Talazoparib in Ps w/ Advanced Solid Tumors; ComBET
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely…
- Ages
- 18 Years - N/A
- Sexes
- All
-
EVOLVE
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid…
- Ages
- 18 Years - 99 Years
- Sexes
- All